GSK’s Tykerb gets priority review

Share this article:
The designation means a decision on Glaxo’s application must come within six months of the drug’s filing date with the FDA, which was Sept. 18. Glaxo is seeking to market Tykerb as a treatment to be used in combination with Roche’s Xeloda for breast cancer that has spread to other parts of the body. Tykerb, if approved, would compete with Roche and Genentech’s rival drug Herceptin. Analysts predict that Tykerb be a $4 billion-a-year seller, depending on how it performs against Herceptin.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.